Summary & Overview
CPT 0580U: Lyme IgG ImmunoBlot for 31 Recombinant Borrelia Proteins
CPT code 0580U designates a Proprietary Laboratory Analyses (PLA) test for the iDart™ Lyme IgG ImmunoBlot Kit from ID–FISH Technology Inc. The assay identifies IgG antibodies to 31 recombinant Borrelia burgdorferi proteins to support diagnosis of past or ongoing Lyme disease infection. As a PLA code, 0580U maps to a single manufacturer-specific test, which has implications for payer coverage, coding specificity, and claims adjudication nationally.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of the test, the likely service setting, and what to expect in payer interactions. The publication outlines common billing modifiers and notes when data are not available in the source input.
This summary provides a national perspective useful to laboratory billing staff, practice managers, and policy analysts seeking clear identification of the test, its intended clinical use, and the payer landscape relevant to authorization and claims processing. It also points to where one would look for benchmarks, coverage policies, and coding guidance if further operational detail is required.
Billing Code Overview
CPT code 0580U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to the iDart™ Lyme IgG ImmunoBlot Kit from ID–FISH Technology Inc. The test detects IgG antibodies against 31 recombinant proteins of Borrelia burgdorferi, the bacterium that causes Lyme disease, and is used to help determine whether a patient has been infected.
Service Type: Specialty laboratory serologic test (proprietary Lyme disease antibody immunoblot).
Typical Site of Service: Clinical laboratory or reference laboratory setting, including independent diagnostic laboratories and hospital laboratories that perform specialty infectious disease serology.
Clinical & Coding Specifications
Clinical Context
A 42-year-old outdoor worker presents to an infectious disease clinic with a 3-week history of intermittent fevers, migrating arthralgias, fatigue, and a history of a recent tick bite while hiking in a Lyme-endemic area. The clinician performs a focused history and physical exam, documents possible early disseminated Lyme disease, and orders serologic testing. The laboratory test ordered is the proprietary iDart™ Lyme IgG ImmunoBlot Kit (0580U) to detect IgG antibodies against 31 recombinant Borrelia burgdorferi proteins. Blood is drawn in the clinic or outpatient phlebotomy unit, labeled with the patient and test identifiers, and sent to the performing laboratory (the specific manufacturer/lab listed for this PLA code). The lab performs the ImmunoBlot assay, interprets band patterns to determine IgG reactivity, and issues a report indicating reactive, nonreactive, or indeterminate results with band-level detail. Results are returned to the ordering clinician, who integrates serology with clinical presentation and other testing (for example, acute vs. convalescent serology or PCR) to assess for Lyme infection and determine further management. Typical site of service includes outpatient clinics, physician offices, and reference laboratories that process PLA tests.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/No modifier | Use when no special circumstance modifier applies to the service. |